Mountain Lake Investment Management Has Increased Cf Inds Hldgs (CF) Holding By $3.38 Million; Shorts at Akers Biosciences (AKER) Raised By 18.65%

December 6, 2017 - By Kurt Siggers

Akers Biosciences Incorporated (NASDAQ:AKER) had an increase of 18.65% in short interest. AKER’s SI was 463,800 shares in December as released by FINRA. Its up 18.65% from 390,900 shares previously. With 413,000 avg volume, 1 days are for Akers Biosciences Incorporated (NASDAQ:AKER)’s short sellers to cover AKER’s short positions. The SI to Akers Biosciences Incorporated’s float is 6.89%. The stock decreased 4.53% or $0.0213 during the last trading session, reaching $0.4484. About 175,430 shares traded. Akers Biosciences, Inc. (NASDAQ:AKER) has declined 16.22% since December 6, 2016 and is downtrending. It has underperformed by 32.92% the S&P500.

Mountain Lake Investment Management Llc increased Cf Inds Hldgs Inc (CF) stake by 250% reported in 2017Q2 SEC filing. Mountain Lake Investment Management Llc acquired 125,000 shares as Cf Inds Hldgs Inc (CF)’s stock declined 16.27%. The Mountain Lake Investment Management Llc holds 175,000 shares with $4.89M value, up from 50,000 last quarter. Cf Inds Hldgs Inc now has $8.61B valuation. The stock decreased 1.25% or $0.465 during the last trading session, reaching $36.895. About 1.31M shares traded. CF Industries Holdings, Inc. (NYSE:CF) has declined 0.63% since December 6, 2016 and is downtrending. It has underperformed by 17.33% the S&P500.

Among 18 analysts covering CF Industries Holdings (NYSE:CF), 6 have Buy rating, 2 Sell and 10 Hold. Therefore 33% are positive. CF Industries Holdings had 85 analyst reports since July 22, 2015 according to SRatingsIntel. The rating was upgraded by UBS to “Buy” on Tuesday, August 23. The firm earned “Sector Perform” rating on Friday, July 24 by RBC Capital Markets. The rating was upgraded by Goldman Sachs on Monday, March 20 to “Buy”. On Friday, July 14 the stock rating was maintained by Piper Jaffray with “Hold”. CLSA upgraded the shares of CF in report on Wednesday, January 27 to “Outperform” rating. The company was upgraded on Wednesday, October 14 by Cowen & Co. RBC Capital Markets maintained it with “Underperform” rating and $27 target in Tuesday, October 17 report. The rating was maintained by Susquehanna on Tuesday, January 26 with “”. As per Tuesday, May 24, the company rating was downgraded by Scotia Capital. The rating was upgraded by Barclays Capital to “Overweight” on Friday, August 14.

Investors sentiment increased to 0.98 in 2017 Q2. Its up 0.03, from 0.95 in 2017Q1. It improved, as 56 investors sold CF shares while 125 reduced holdings. 56 funds opened positions while 122 raised stakes. 255.28 million shares or 3.32% more from 247.08 million shares in 2017Q1 were reported. Ohio-based Gateway Investment Advisers Ltd Liability has invested 0% in CF Industries Holdings, Inc. (NYSE:CF). Metropolitan Life Insurance Company holds 113,037 shares or 0.02% of its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) reported 0.31% stake. 175,000 were reported by Mountain Lake Inv Mngmt Lc. Vanguard Gru Inc holds 24.16 million shares. Fincl Bank Of America De, a North Carolina-based fund reported 1.09 million shares. Ameriprise has 1.65M shares for 0.02% of their portfolio. Panagora Asset has 49,393 shares. Dnb Asset Mgmt As invested 0% in CF Industries Holdings, Inc. (NYSE:CF). Guardian Life Ins Com Of America has 0% invested in CF Industries Holdings, Inc. (NYSE:CF) for 523 shares. Norinchukin Commercial Bank The reported 16,178 shares or 0.01% of all its holdings. Riverpark Limited Liability owns 79,200 shares. Employees Retirement Systems Of Texas holds 0.01% or 17,000 shares. Oppenheimer & stated it has 0.15% in CF Industries Holdings, Inc. (NYSE:CF). 21,218 were reported by Innovations Ltd.

Akers Biosciences, Inc., together with its subsidiaries, develops, makes, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and clients in the United States and internationally. The company has market cap of $6.29 million. The companyÂ’s marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. It currently has negative earnings. The Company’s marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol ‘CheckÂ’, a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.